Therapeutic CD8 <sup>+</sup> T cell tissue retention and immunomodulation during ART interruption fail to prevent SIV rebound

M M. Betina Pampena (Department of Microbiology, Perelman School of Medicine, University of Pennsylvania) S Sadia Samer (Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University) E Elise G. Viox (Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University) K Kevin Nguyen (Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University) C Claire Deleage (AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc.) L Leticia Kuri-Cervantes (Department of Microbiology, Perelman School of Medicine, University of Pennsylvania) J James Regan (Department of Microbiology, Perelman School of Medicine, University of Pennsylvania) V Vincent H. Wu (Department of Microbiology, Perelman School of Medicine, University of Pennsylvania) S Steffen Docken (Infection Analytics Program, Kirby Institute for Infection and Immunity, University of New South Wales) J Jeffrey T. Safrit (ImmunityBio, Inc.) K Katharine J. Bar (Department of Microbiology, Perelman School of Medicine, University of Pennsylvania) B Brandon F. Keele M Miles P. Davenport (Infection Analytics Program, Kirby Institute for Infection and Immunity, University of New South Wales) M Mirko Paiardini (Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University) M Michael R. Betts (Department of Microbiology, Perelman School of Medicine, University of Pennsylvania)

Abstract

A primary obstacle for HIV elimination is the long-term viral reservoir in lymphoid tissues (LT) that can cause rebound viremia if therapy is stopped. Cytotoxic CD8 + T cells are critical for control of HIV and Simian immunodeficiency virus (SIV) viremia; however, CD8 + T cells that migrate to LT are primarily noncytotoxic, calling into question whether these cells could reduce the viral reservoir on antiretroviral therapy (ART) or control viral replication when therapy is halted. To determine whether CD8 + T cells can inhibit viral replication when retained in LT, we inhibited lymphocyte egress from LTs in ART-treated SIV-infected rhesus macaques (RMs) during analytic treatment interruption (ATI) using the S1PR modulator FTY720 alone or in combination with anti-PD1 antibody (αPD1) and the IL-15 receptor superagonist N-803 to increase cytolytic function. FTY720 retained migrating CD4 + and CD8 + T cells in LT, whereas cytotoxic CD8 + T cells remained in the vasculature. After ATI and viral rebound, activated SIV-specific CD8 + T cells increased in frequency in LT of FTY720-treated RMs but failed to become cytotoxic or control plasma viremia compared to controls, even when combined with αPD1 and N-803. These findings indicate that LT-localized CD8 + T cells alone may be insufficient to delay or prevent plasma viral rebound during ATI.

Article Details

Volume / Issue Vol. 122, Issue 33
Published August 19, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (15)

M

M. Betina Pampena

Department of Microbiology, Perelman School of Medicine, University of Pennsylvania

S

Sadia Samer

Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University

E

Elise G. Viox

Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University

K

Kevin Nguyen

Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University

C

Claire Deleage

AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc.

L

Leticia Kuri-Cervantes

Department of Microbiology, Perelman School of Medicine, University of Pennsylvania

J

James Regan

Department of Microbiology, Perelman School of Medicine, University of Pennsylvania

V

Vincent H. Wu

Department of Microbiology, Perelman School of Medicine, University of Pennsylvania

S

Steffen Docken

Infection Analytics Program, Kirby Institute for Infection and Immunity, University of New South Wales

J

Jeffrey T. Safrit

ImmunityBio, Inc.

K

Katharine J. Bar

Department of Microbiology, Perelman School of Medicine, University of Pennsylvania

B

Brandon F. Keele

M

Miles P. Davenport

Infection Analytics Program, Kirby Institute for Infection and Immunity, University of New South Wales

M

Mirko Paiardini

Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University

M

Michael R. Betts

Department of Microbiology, Perelman School of Medicine, University of Pennsylvania